List of Excipients in Branded Drug VALPROATE SODIUM

Generic Drugs Containing VALPROATE SODIUM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	valproate sodium	0143-9637	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc	valproate sodium	0143-9637	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	valproate sodium	0143-9637	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	valproate sodium	0143-9637	WATER

What are the Most Frequently-Used Excipients in VALPROATE SODIUM?

# Of NDCs	Excipient
5	EDETATE DISODIUM
5	HYDROCHLORIC ACID
5	SODIUM HYDROXIDE
4	WATER

Valproate Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Valproate sodium is a mature antiseizure active pharmaceutical ingredient with limited opportunity for new-chemical-entity exclusivity. Commercial value is concentrated in differentiated delivery systems, pediatric acceptability, ready-to-use injectable products, modified release, dose flexibility, and manufacturing reliability. The strongest opportunities are formulation improvements that reduce dosing friction while preserving bioavailability, chemical stability, and regulatory comparability.

What is the commercial position of valproate sodium?

Valproate sodium is the sodium salt of valproic acid and is used primarily in intravenous and oral dosage forms. FDA-approved valproate products cover epilepsy and seizure disorders; related valproate products, including divalproex sodium, also cover bipolar mania and migraine prophylaxis depending on the product and label. Valproate carries significant reproductive and hepatotoxicity warnings, which affect prescribing, labeling, pediatric development, and market-access strategy (FDA, 2024a; FDA, 2024b).

Attribute	Commercial implication
Active ingredient	Valproate sodium
Therapeutic class	Antiseizure medication
Primary dosage forms	Injection, oral solution, capsules, tablets, delayed-release and extended-release products
Key administration issue	Oral administration may be temporarily unavailable in hospitalized patients
Main formulation risks	Taste, gastrointestinal tolerability, dose-volume burden, moisture sensitivity, release control and chemical stability
Regulatory position	Mature, genericized active ingredient with product-specific FDA approvals
Main differentiation route	Formulation, device, packaging, manufacturing process and patient-use profile
Principal safety constraint	Teratogenicity and other serious valproate-related warnings

The injectable product is particularly relevant to hospitals because it is used when oral administration is temporarily impractical. Oral products compete on dose flexibility, swallowability, taste, adherence, and release profile.

What excipients are used in valproate sodium products?

Excipient selection depends on dosage form and target label. Valproate sodium formulations do not have one universal excipient system.

Injectable valproate sodium

Commercial valproate sodium injection is generally designed as an aqueous parenteral solution. The formulation priorities are low particulate burden, chemical stability, controlled pH, sterility, container compatibility and rapid preparation.

Potential excipient functions include:

Function	Candidate excipient classes	Development considerations
pH adjustment	Sodium hydroxide, hydrochloric acid or other approved pH adjusters	pH affects stability, solubility, irritation and container compatibility
Tonicity adjustment	Sodium chloride or other tonicity agents	Must account for sodium load and total osmolarity
Solubilization	Water for injection and, where justified, selected co-solvents	Parenteral safety and precipitation risk restrict the design space
Chelation	EDTA-type chelators where justified	May affect regulatory review, compatibility and stability
Antioxidant protection	Product-specific antioxidant systems	Requires evidence because valproate degradation pathways and oxygen sensitivity must be established
Container protection	Low-extractable glass, polymer or closure systems	Packaging is part of the stability strategy

The approved label for an injectable product must control the strategy. For a generic injection, adding or removing an excipient can create a formulation and sameness issue under the ANDA pathway, particularly if the change affects inactive-ingredient safety, route-of-administration compatibility or product performance (FDA, 2019).

Oral solutions and syrups

Oral liquids offer the broadest excipient opportunity because taste and dose administration are major barriers. Useful excipient categories include:

• Sweeteners, including sucrose, sorbitol, sucralose or other approved systems
• Humectants, such as glycerin or propylene glycol where permitted
• Viscosity modifiers
• Flavor systems
• Buffers and pH adjusters
• Preservatives for multidose containers
• Chelators or antioxidants where stability data support their use
• Sugar-free and alcohol-free vehicle systems

The central challenge is balancing taste masking with chemical stability and dose accuracy. A high-sweetener system may improve acceptability but increase caloric exposure, dental concerns or osmolality. Polyol-heavy systems can create gastrointestinal tolerability issues. Flavor systems can also interact with packaging or change over shelf life.

For pediatric use, the highest-value design is usually a low-volume, dose-flexible, sugar-free and alcohol-free solution with a dosing syringe and a taste profile that supports repeated administration.

Tablets, capsules and multiparticulates

Solid oral formulations can use conventional fillers, binders, disintegrants, lubricants and film coatings. More differentiated strategies include:

• Taste-masked granules or coated particles
• Sprinkle capsules for patients with swallowing difficulty
• Mini-tablets for pediatric dose titration
• Multiparticulate modified-release systems
• Low-dust manufacturing for occupational and production control
• Film coatings that reduce odor and improve swallowability

Valproate sodium is highly dose-dependent in many clinical settings. A formulation that allows 50 mg or 100 mg dose increments can have more commercial value than a marginal change in tablet size.

What formulations are protected by valproate sodium patents?

Formulation protection is more commercially relevant than active-ingredient protection. Potential claim categories include:

1. Specific excipient ratios.
2. Modified-release matrices or coated multiparticulates.
3. Particle-size distributions.
4. Taste-masking coatings.
5. Low-water or controlled-moisture compositions.
6. Stable aqueous injectable solutions.
7. Ready-to-use infusion presentations.
8. Container-closure systems.
9. Administration devices and dosing mechanisms.
10. Manufacturing processes that reduce degradation products or improve content uniformity.

The most defensible formulation patents usually combine a composition limitation with a measurable performance requirement, such as dissolution, impurity profile, release duration, viscosity, osmolality or stability after storage.

A broad claim covering “valproate sodium with pharmaceutical excipients” is unlikely to provide strong protection for a mature generic ingredient. Narrower claims tied to a clinically meaningful delivery advantage have greater licensing and enforcement value.

When does valproate sodium lose exclusivity?

Valproate sodium has long lost any meaningful new-chemical-entity exclusivity. Commercial exclusivity now depends on the individual product, dosage form, formulation and jurisdiction.

Exclusivity category	Relevance to valproate sodium
NCE exclusivity	Expired for the mature active ingredient
Orphan exclusivity	Product- and indication-specific; not inherent to valproate sodium
Pediatric exclusivity	Possible only if separately awarded for a qualifying product
New formulation patents	May remain relevant for modified-release or specialized products
Method-of-use patents	May cover a specific indication, population or dosing method
ANDA exclusivity	May apply to a first approved generic product with qualifying exclusivity
Regulatory exclusivity	Must be checked against the individual FDA product approval

The Orange Book lists patents and exclusivity by reference-listed drug, not as a single patent estate for every valproate sodium product. Any launch assessment must therefore identify the target reference product and dosage form before evaluating patent expiry or Paragraph IV exposure (FDA, 2024c).

What is the Orange Book status of valproate sodium?

The FDA Orange Book should be searched by product name, active ingredient, dosage form and applicant. Relevant searches may include valproate sodium injection, valproic acid oral solution, divalproex sodium delayed-release tablets and divalproex sodium extended-release tablets.

Orange Book analysis should distinguish:

• The active ingredient from the finished dosage form
• Valproate sodium from valproic acid and divalproex sodium
• Listed patents from expired patents
• Drug substance patents from formulation or method-of-use patents
• Patents with remaining term from patents subject to pediatric extension
• Product-specific listing status from actual enforceability

A Paragraph IV certification is relevant only when an ANDA applicant challenges a listed patent for the specific reference-listed drug. It does not challenge every patent associated with valproate chemistry.

Which companies are challenging valproate sodium patents?

Valproate sodium has a large generic market, but a current company-by-company Paragraph IV assessment requires a live Orange Book, FDA approval-history and court-docket review. Generic competition has historically included large and specialty manufacturers across oral and injectable dosage forms.

The most relevant competitive groups are:

• Large generic manufacturers supplying tablets, capsules and oral solutions
• Hospital-focused manufacturers supplying sterile injection
• Branded manufacturers retaining differentiated divalproex products
• Contract manufacturers with controlled-release and multiparticulate capabilities
• Specialty companies pursuing pediatric or adherence-oriented presentations

Patent litigation risk is likely to concentrate around modified-release products, formulation-specific claims and listed method-of-use patents rather than the basic valproate sodium molecule.

What commercial opportunities exist for new valproate sodium excipients?

Pediatric taste masking

A pediatric formulation can target liquid administration, dose flexibility and reduced administration volume. Commercially useful claims may cover:

• A specific taste-masking system
• Coated drug particles suspended in a stable vehicle
• A dosing syringe calibrated for small volumes
• Improved palatability without ethanol
• Sugar-free administration
• Reduced sedimentation and redispersibility requirements

The safety profile of valproate means that pediatric positioning must be indication-specific and consistent with current labeling and reproductive-risk controls.

Ready-to-use injectable products

Hospitals may value premixed or ready-to-administer presentations that reduce preparation steps, dosing errors and pharmacy workload. Potential products include:

• Ready-to-use bags
• Pre-filled syringes
• Standardized concentrations
• Closed-system transfer presentations
• Compatible infusion containers
• Low-overfill, waste-reducing configurations

The commercial case depends on hospital purchasing, supply reliability, compatibility data and whether the product qualifies for meaningful workflow savings.

Modified-release oral products

Extended-release and delayed-release products can compete through reduced dosing frequency, smoother exposure and improved adherence. Patentable technical features may include:

• Hydrophilic or lipid matrix systems
• Polymer-coated granules
• Osmotic or diffusion-controlled delivery
• Dose-independent release behavior
• Food-effect mitigation
• Reduced peak-related tolerability problems

Bioequivalence and clinical performance are the principal barriers. A modified-release formulation with a distinct pharmacokinetic profile may require more extensive development than a conventional ANDA.

Flexible-dose sprinkle products

Sprinkle capsules and multiparticulate products can address dysphagia, pediatric use and feeding-tube administration. The formulation must preserve dose uniformity, avoid premature release and maintain stability after opening or mixing with permitted foods.

Excipients with supply-chain advantages

A formulation using widely available, pharmacopeial-grade excipients can reduce supply risk. A differentiated excipient strategy should avoid unnecessary dependence on a single supplier, especially for specialty coatings, flavors, preservatives and parenteral components.

How strong is the patent estate for valproate sodium?

The underlying valproate sodium patent estate is weak as a composition-of-matter platform because the ingredient is mature. Product-level protection can still be commercially meaningful when it combines:

• A difficult-to-reproduce release profile
• A validated stability advantage
• A device or packaging limitation
• A pediatric administration benefit
• A manufacturing process that is difficult to design around
• A clinically relevant reduction in dosing frequency

Patent strength should be evaluated using claim breadth, prior-art density, enablement, written description, obviousness exposure, freedom-to-operate results and the availability of noninfringing formulation routes.

Manufacturing trade secrets may provide more durable protection than patents for particle coating, process controls, impurity reduction and scale-up parameters. Trade-secret protection is most valuable where reverse engineering from the finished dosage form is difficult.

How does valproate sodium compare with divalproex sodium and valproic acid?

Product form	Main commercial advantage	Main formulation challenge
Valproate sodium	Injectable and oral salt presentations; rapid hospital utility	Sodium load, parenteral compatibility and solution stability
Valproic acid	Established oral liquid and capsule use	Taste, odor, irritation and liquid stability
Divalproex sodium	Delayed-release and extended-release product platforms	Release control, food effects and bioequivalence
New multiparticulate valproate	Dose flexibility and swallowing support	Coating robustness and regulatory comparability

The closest commercial comparator depends on the indication and route. Valproate sodium injection competes primarily with other sterile valproate presentations and hospital procurement alternatives. Oral valproate sodium competes with valproic acid and divalproex products based on dosage form, dosing frequency and tolerability.

What FDA regulatory issues affect excipient commercialization?

FDA review will focus on inactive-ingredient safety, route-specific acceptability, product performance, stability, manufacturing controls and bioequivalence. The regulatory pathway depends on whether the product is an equivalent generic, a modified formulation, a new presentation or a product requiring clinical support.

Key development controls include:

• Excipient qualification under current good manufacturing practice
• ICH stability studies
• Extractables and leachables assessment
• Container-closure integrity for injections
• Microbial limits and preservative effectiveness for oral liquids
• Dissolution and release testing for modified-release products
• Comparative pharmacokinetic studies where applicable
• Human factors validation for dosing devices
• Control of degradation products and elemental impurities (ICH, 2009; ICH, 2015)

What generic entry risks exist for valproate sodium?

Generic entry risk is high for conventional immediate-release products with no meaningful remaining patent barriers. Risk is lower for technically complex products, including:

• Sterile injectable presentations
• Modified-release tablets
• Multiparticulate products
• Stable, low-volume pediatric liquids
• Products requiring device integration
• Formulations with difficult dissolution or pharmacokinetic targets

Commercial forecasts should separate unit-volume erosion from price erosion. A new formulation may retain value even in a heavily genericized market if it earns hospital formulary preference, pediatric adoption or reimbursement based on administration savings.

Key Takeaways

• Valproate sodium is a mature, genericized active ingredient with limited molecule-level exclusivity.
• The strongest commercial opportunities are formulation and delivery improvements.
• Pediatric taste masking, sugar-free liquids, sprinkle systems, modified release and ready-to-use injections are the most credible opportunity areas.
• Injectable products require close control of pH, sterility, sodium load, container compatibility and stability.
• Formulation patents should claim measurable technical performance rather than broad excipient combinations.
• Orange Book and Paragraph IV analysis must be conducted at the reference-product and dosage-form level.
• Generic entry risk is high for conventional oral products and more moderate for complex modified-release and sterile presentations.
• Manufacturing know-how may be more defensible than broad composition patents.

FAQs

Can valproate sodium be formulated as a sugar-free pediatric liquid?

Yes. A sugar-free liquid can use polyols, high-intensity sweeteners, flavors, viscosity modifiers and preservatives where justified. The design must control taste, osmolality, gastrointestinal tolerability, microbial stability and dosing accuracy.

Are excipient patents available for valproate sodium?

Yes, but protection generally must focus on a specific composition, release profile, stability result, device or manufacturing process. Broad claims covering valproate sodium with routine pharmaceutical excipients face substantial prior-art and obviousness risk.

Is valproate sodium injection suitable for a ready-to-use presentation?

Potentially. A ready-to-use product requires evidence on container compatibility, particulate control, sterility assurance, stability, infusion compatibility, dose concentration and administration instructions.

Does valproate sodium require a biosimilar strategy?

No. Valproate sodium is a small-molecule drug, not a biologic. Competitive products generally follow generic-drug pathways rather than biosimilar pathways.

Which valproate product has the greatest excipient-driven differentiation potential?

Pediatric oral liquids and multiparticulate products generally offer the broadest excipient-driven differentiation. Ready-to-use injectable products can also create commercial value through hospital workflow, safety and waste reduction.

References

1. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptides: Guidance for industry. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024a). Valproate sodium injection prescribing information. U.S. Department of Health and Human Services. DailyMed.

3. Food and Drug Administration. (2024b). Depakote prescribing information. U.S. Department of Health and Human Services. DailyMed.

4. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.

6. International Council for Harmonisation. (2015). ICH Q3D: Guideline for elemental impurities.